Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusiness

Zydus Cadila gets tentative USFDA nod for diabetes drug

The United States Food and Drug Administration (USFDA) has granted tentative approval to market the drug in strengths of 2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/ 1,000 mg, Cadila Healthcare said in a BSE filing.

October 12, 2018 / 12:00 PM IST

Drug firm Zydus Cadila Friday said it has received tentative approval from the US health regulator to market Linagliptin and Metformin Hydrochloride tablets, used to control of blood sugar levels in diabetic patients.

The United States Food and Drug Administration (USFDA) has granted tentative approval to market the drug in strengths of 2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/ 1,000 mg, Cadila Healthcare said in a BSE filing.

Zydus Cadila said the drug will be produced at the group's formulations manufacturing facility at special economic zone (SEZ), Ahmedabad.

The group has more than 221 approvals, and so far filed over 330 abbreviated new drug applications (ANDAs) since it started filings in 2003-04.

Shares of Cadila Healthcare, the listed entity of the group, were trading 0.73 percent higher at Rs 378.20 apiece on BSE.

PTI
first published: Oct 12, 2018 11:57 am

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347